Spectrascience New Financials
| SCIEDelisted Stock | USD 1.42 0.00 0.00% |
Spectrascience |
Please note, the presentation of Spectrascience New's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spectrascience New's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Spectrascience New's management manipulating its earnings.
Spectrascience New Stock Summary
SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California. Spectrascience operates under Medical Appliances Equipment classification in the United States and is traded on OTC Exchange. It employs 5 people.| Instrument | USA Stock View All |
| Exchange | OTCCE Exchange |
| ISIN | US84760E3018 |
| Business Address | 11568 Sorrento Valley |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.spectrascience.com |
| Phone | 858 847 0200 |
| Currency | USD - US Dollar |
Spectrascience New Key Financial Ratios
| Return On Asset | -0.92 | |||
| Beta | 35.35 |
Spectrascience Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Spectrascience New's current stock value. Our valuation model uses many indicators to compare Spectrascience New value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Spectrascience New competition to find correlations between indicators driving Spectrascience New's intrinsic value. More Info.Spectrascience New is rated below average in return on asset category among its peers. It is rated fifth in current valuation category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Spectrascience New by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Spectrascience New Financials
What exactly are Spectrascience New Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Spectrascience New's income statement, its balance sheet, and the statement of cash flows. Potential Spectrascience New investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Spectrascience New investors may use each financial statement separately, they are all related. The changes in Spectrascience New's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Spectrascience New's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Spectrascience New January 18, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Spectrascience New help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Spectrascience New. We use our internally-developed statistical techniques to arrive at the intrinsic value of Spectrascience New based on widely used predictive technical indicators. In general, we focus on analyzing Spectrascience Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Spectrascience New's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.64 | |||
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 8.4 | |||
| Value At Risk | (2.05) | |||
| Potential Upside | 1.45 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Spectrascience Stock
If you are still planning to invest in Spectrascience New check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spectrascience New's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |